AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 10368993
Drug: H2-receptor antagonist
RxNorm normalized name: H2-receptor antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H2-receptor antagonist (H2-RA)
Trial: 8813472
Drug: OCT radionuclide
RxNorm normalized name: Urimar Reformulated Oct 2013
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OCT radionuclide therapy
Trial: 6397178
Drug: Acarbose 300
RxNorm normalized name: Acarbose
DrugBank: Acarbose (DB00284)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acarbose 300 mg/day for one month
Trial: 6397178
Drug: Acarbose 100-400
RxNorm normalized name: acarbose 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acarbose 100-400 mg/day for six months
Trial: 31108379
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural therapy (CBT) combined with medication (n = 92)
Trial: 31108379
Drug: Medication alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication alone (n = 75)
Trial: 27510285
Drug: Low-dose UVA-1
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose UVA-1 phototherapy (30 J/cm2, 340-400 nm) - 30 sessions
Trial: 22309796
Drug: Culturally-appropriate family-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Culturally-appropriate family-based interventions developed through community collaboration; specific dosage and duration not mentioned.
Trial: 17659972
Drug: Long-term treatment
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term treatment (continue steroids once daily for 12 months)
Trial: 17659972
Drug: Short-term treatment
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term treatment (stop topical steroid treatment)
Trial: 10102462
Drug: Fish diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish diet alone (3.6 g omega3 fatty acids/day)
Trial: 10102462
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of fish diet and moderate exercise
Trial: 7597630
Drug: Titaniumtetrafluoride solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Titaniumtetrafluoride solution
Trial: 2185664
Drug: Protein refeeding
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein refeeding (80 g protein)
Trial: 2185664
Drug: Carbohydrate refeeding
RxNorm normalized name: pyrrolidone carboxylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate refeeding (80 g carbohydrate)
Trial: 7093110
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg aspirin
Trial: 26175097
Drug: NZBC extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NZBC extract (300 mg day(‐1) CurraNZ™ containing 105 mg anthocyanin)
Trial: 26175097
Drug: Placebo (PL,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (PL, 300 mg microcrystalline cellulose M102)
Trial: 24749261
Drug: Epidural infusion
RxNorm normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural infusion of naropine
Trial: 7521832
Drug: Emergency treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emergency treatment of seizures and aggressive treatment of fever
Trial: 7521832
Drug: Treatment with
RxNorm normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with an antiepileptic drug
Trial: 2844494
Drug: Conversion enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conversion enzyme inhibitor
Trial: 29462158
Drug: 600 mg/day
RxNorm normalized name: Rebetron, single dose 600 mg/day oral and injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg/day DHA (from algal oil) for 16 weeks
Trial: 16835968
Drug: DVd regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DVd regimen with thalidomide (50 mg/d orally, increased to a maximum of 400 mg/d)
Trial: 12639763
Drug: HRT (conjugated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRT (conjugated equine oestrogen 0.625 mg and medroxyprogesterone acetate 2.5 mg)
Trial: 10928223
Drug: Daily 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily 2.5 mg risedronate
Trial: 10928223
Drug: Cyclical 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclical 15 mg risedronate (2 out of 12 weeks)
Trial: 1533165
Drug: High thoracic
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High thoracic epidural analgesia (TEA) with bupivacaine 0.375% plus sufentanil 1:200,000 (5 micrograms/mL) combined with general anesthesia (midazolam/N2O)
Trial: 29609070
Drug: Reverse hybrid
RxNorm normalized name: OraVerse
DrugBank: Phentolamine (DB00692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reverse hybrid therapy (proton pump inhibitor plus amoxicillin for 14 days, and clarithromycin plus metronidazole for the initial 7 days)
Trial: 29609070
Drug: Bismuth quadruple
RxNorm normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bismuth quadruple therapy (pantoprazole, bismuth, tetracycline, and metronidazole for 14 days)
Trial: 26632893
Drug: Reverse hybrid
RxNorm normalized name: OraVerse
DrugBank: Phentolamine (DB00692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reverse hybrid therapy
Trial: 31523279
Drug: Bismuth quadruple
RxNorm normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bismuth quadruple therapy
Trial: 24055515
Drug: Site-reported duplex
RxNorm normalized name: black imported fire ant allergenic extract
DrugBank: Solenopsis richteri (DB11026)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Site-reported duplex ultrasound (DU) scans prior to treatment
Trial: 24055515
Drug: UCL review
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UCL review of prior-to-treatment scans
Trial: 7589048
Drug: Piroxicam 10
RxNorm normalized name: piroxicam 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piroxicam 10 mg
Trial: 16962674
Drug: AV sequential
RxNorm normalized name: AVS-100
DrugBank: AVS-100 (DB18068)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AV sequential pacing at septum (DDDspt)
Trial: 16962674
Drug: AV sequential
RxNorm normalized name: AVS-100
DrugBank: AVS-100 (DB18068)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AV sequential pacing at RV apex (DDDapx)
Trial: 12394665
Drug: Early active
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early active treatment program
Trial: 8852495
Drug: Doxazosin (Cardura)
RxNorm normalized name: doxazosin Oral Tablet [Cardura]
DrugBank: Doxazosin (DB00590)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxazosin (Cardura) 2-8 mg once daily or 8 mg b.i.d.
Trial: 8852495
Drug: Captopril (Capoten)
RxNorm normalized name: Captopril
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Captopril (Capoten) 25-50 mg b.i.d.
Trial: 8852495
Drug: Nifedipine (Procardia-XL)
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine (Procardia-XL) 30-60 mg once daily
Trial: 31004340
Drug: Extracorporeal shock
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extracorporeal shock wave therapy (ESWT) combined with pharmacotherapy (alpha-blocker, anti-inflammatory agent, muscle relaxant, short course of antibiotic)
Trial: 31004340
Drug: Sham-ESWT combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham-ESWT combined with pharmacotherapy
Trial: 22633423
Drug: Fibrin sealant
RxNorm normalized name: FIBRIN SEALANT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrin sealant (FS) containing 500 IU/mL thrombin and synthetic aprotinin
Trial: 17678487
Drug: Antiplatelet agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiplatelet agents (i.e., clopidogrel)
Trial: 17678487
Drug: Cholesterol-lowering agents
RxNorm normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholesterol-lowering agents (i.e., statins)
Trial: 2796617
Drug: 0.5% tetracaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% tetracaine 10 mg in hyperbaric solution
Trial: 2796617
Drug: 0.5% tetracaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% tetracaine 10 mg in isobaric solution
Trial: 356246
Drug: Diclofenac sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac sodium (Voltaren, 25 mg t.i.d.)
Trial: 7044798
Drug: Indomethacin (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (25 mg t.i.d.)
Trial: 20820817
Drug: Tetracycline 500
RxNorm normalized name: oxytetracycline 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetracycline 500 mg orally twice a day for 28 days
Trial: 11509491
Drug: Transdermal clonidine
RxNorm normalized name: clonidine Transdermal System
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal clonidine patch (14 patients)
Trial: 11509491
Drug: Transdermal placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal placebo (12 patients)
Trial: 8111799
Drug: Quinapril 10.0,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinapril 10.0, 20.0, or 40.0 mg, or 20 mg plus 12.5 mg hydrochlorothiazide (HCTZ) given once daily
Trial: 8111799
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg quinapril daily or 20 mg quinapril plus 12.5 mg HCTZ daily
Trial: 31847158
Drug: Standard physical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard physical therapy (control group)
Trial: 2682025
Drug: Triiodothyronine administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triiodothyronine administration at the end of operation and during the initial 24 hours after operation (study I)
Trial: 2682025
Drug: Triiodothyronine administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triiodothyronine administration (study II)
Trial: 180405
Drug: High dosage
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dosage intermittent polychemotherapy, given as 3 infusions at intervals of a week for 3 years.
Trial: 31944580
Drug: suvorexant 10
RxNorm normalized name: suvorexant 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: suvorexant 10 mg (could be increased to 20 mg based on clinical response)
Trial: 27823800
Drug: Methylcobalamin 1000
RxNorm normalized name: METHYLCOBALAMIN 1000MCG CHEWABLE TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylcobalamin 1000 μg once daily for 27 months
Trial: 27823800
Drug: Placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets once daily for 27 months
Trial: 27823800
Drug: Methylcobalamin 1000
RxNorm normalized name: METHYLCOBALAMIN 1000MCG CHEWABLE TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylcobalamin 1000 μg
Trial: 26056336
Drug: In-treatment SBP
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In-treatment SBP ≤130 mm Hg
Trial: 26056336
Drug: In-treatment SBP
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In-treatment SBP 131 to 141 mm Hg
Trial: 26056336
Drug: In-treatment SBP
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In-treatment SBP ≥142 mm Hg
Trial: 20619924
Drug: Annual low
RxNorm normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Annual low dose chest CT scans (CT group)
Trial: 19572228
Drug: human follicle
RxNorm normalized name: Human follicle stimulating hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: human follicle stimulating hormone (hFSH)
Trial: 15113814
Drug: Tolvaptan 30
RxNorm normalized name: tolvaptan 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolvaptan 30 mg/d
Trial: 15113814
Drug: Tolvaptan 60
RxNorm normalized name: tolvaptan 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolvaptan 60 mg/d
Trial: 15113814
Drug: Tolvaptan 90
RxNorm normalized name: tolvaptan 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolvaptan 90 mg/d
Trial: 15113814
Drug: Tolvaptan (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolvaptan (all doses)
Trial: 11353629
Drug: Intramuscular quinine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular quinine dihydrochloride (20 mg/kg of body weight)
Trial: 23183442
Drug: Intramuscular quinine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular quinine
Trial: 3500051
Drug: Methotrexate intravenous
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate intravenous bolus test doses (50 mg/m2) with folinic acid (15 mg every 6 h)
Trial: 3500051
Drug: Methotrexate intravenous
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate intravenous bolus test doses (50 mg/m2) without folinic acid
Trial: 3500051
Drug: 8 h
RxNorm normalized name: Tylenol 8 Hour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 h infusion of methotrexate individualized to achieve a peak plasma concentration of 5 X 10(‐4) M
Trial: 11496234
Drug: L-NMMA (inhaled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-NMMA (inhaled nitric oxide synthase inhibitor)
Trial: 9284163
Drug: CVD 111
RxNorm normalized name: Vibrio cholerae CVD 103-HGR strain live antigen Oral Suspension [Vaxchora]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CVD 111 at high dose
Trial: 9284163
Drug: CVD 111
RxNorm normalized name: Vibrio cholerae CVD 103-HGR strain live antigen Oral Suspension [Vaxchora]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CVD 111 at low dose
Trial: 26765630
Drug: Mirror Training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirror Training Group (MG)
Trial: 22374408
Drug: TAK-875 (6·25,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-875 (6·25, 25, 50, 100, or 200 mg)
Trial: 18519992
Drug: Essential dental
RxNorm normalized name: Eucalyptus essential oil
DrugBank: Eucalyptus oil (DB11114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Essential dental treatment (EDT) at 13 to 21 weeks' gestation
Trial: 18519992
Drug: Topical or
RxNorm normalized name: aloe vera topical oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical or local anesthetics during root planing
Trial: 18519992
Drug: EDT and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EDT and periodontal treatment
Trial: 18519992
Drug: EDT or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EDT or periodontal treatment alone
Trial: 8647365
Drug: Low-dose aspirin
RxNorm normalized name: low-dose aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose aspirin treatment
Trial: 6369594
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy with DTIC and cyclophosphamide (600 mg/m2 administered intravenously every 3 weeks for nine cycles)
Trial: 6369594
Drug: Adjuvant immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant immunotherapy with Corynebacterium parvum (4 mg/m2 divided among the four extremities in 1- to 2-week cycles)
Trial: 6369594
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy with DTIC and cyclophosphamide
Trial: 6369594
Drug: Adjuvant immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant immunotherapy with Corynebacterium parvum
Trial: 31175052
Drug: Anthracycline chemotherapy
RxNorm normalized name: methacycline
DrugBank: Metacycline (DB00931)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anthracycline chemotherapy (doxorubicin)
Trial: 31175052
Drug: Non-anthracycline taxane
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-anthracycline taxane chemotherapy
Trial: 29231163
Drug: Novel lyophilized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel lyophilized rapid-disintegrating tablet (bup-lyo)
Trial: 29231163
Drug: Standard sublingual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard sublingual buprenorphine tablet (bup-SL)
Trial: 27099473
Drug: DLBS3233 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DLBS3233 at a dose of 50‐100 mg daily
Trial: 12483466
Drug: Pravastatin 40
RxNorm normalized name: pravastatin 40 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin 40 mg/day for 6 months
Trial: 16061593
Drug: L-aspartic acid
RxNorm normalized name: L-Aspartic Acid
DrugBank: Aspartic acid (DB00128)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-aspartic acid (6 doses per day, 5 mL per dose)
Trial: 16061593
Drug: Enzymatically hydrolyzed
RxNorm normalized name: hydrolyzed sericin (enzymatic; 2500 MW)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enzymatically hydrolyzed casein (EHC) (6 doses per day, 5 mL per dose)
Trial: 16061593
Drug: Whey/casein (W/C)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey/casein (W/C) (6 doses per day, 5 mL per dose)
Trial: 16061593
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no beta-glucuronidase inhibitors)
Trial: 1726009
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg of lacidipine
Trial: 30526230
Drug: Riluzole 50
RxNorm normalized name: riluzole 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Riluzole 50 mg twice daily for 12 weeks
Trial: 27775818
Drug: Rifaximin 550
RxNorm normalized name: rifAXIMin 550 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifaximin 550 mg twice a day
Trial: 24470753
Drug: Itopride 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itopride 150 mg ER once daily under fasting conditions
Trial: 24470753
Drug: Itopride 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itopride 50 mg IR three times daily in fasting state
Trial: 24470753
Drug: Itopride 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itopride 150 mg ER once daily under fed conditions
Trial: 22392817
Drug: High levels
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High levels of interleukin-6 (IL-6) soluble receptor (SR)
Trial: 17627164
Drug: Fluoxetine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (20 mg daily for 4 weeks, then 20 mg as needed 2-3 hours before sexual activity for 4 months)
Trial: 17627164
Drug: Fluoxetine combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine combined with sildenafil (50 mg as needed 1 hour before sexual activity for 4 months)
Trial: 15855258
Drug: 17beta‐estradiol (E2;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17beta‐estradiol (E2; 2 mg, followed by 4 mg)
Trial: 15855258
Drug: Raloxifene (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene (60 mg, followed by 120 mg)
Trial: 11339909
Drug: 2% vaginal
RxNorm normalized name: XACIATO 2% Vaginal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% vaginal clindamycin cream for 7 days
Trial: 11339909
Drug: Identical placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical placebo cream for 7 days
Trial: 10374456
Drug: Twice-daily theophylline
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily theophylline dosing (TD)
Trial: 10374456
Drug: Once-daily theophylline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily theophylline dosing (OD)
Trial: 30166366
Drug: Oral glucose
RxNorm normalized name: glucose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glucose alone or combined with maternal holding
Trial: 30166366
Drug: Maternal-infant relationship
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maternal-infant relationship (combined with oral glucose and breastfeeding)
Trial: 24286965
Drug: Continuous glucose
RxNorm normalized name: sub-q infusion pump w/continuous glucose monitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous glucose monitoring (subcutaneous continuous monitoring system)
Trial: 12905095
Drug: 175 g
RxNorm normalized name: ALCOHOL 14.175 g in 10 / BENZALKONIUM CHLORIDE 0.042 g in 10 / DIDECYLDIMONIUM CHLORIDE 0.0567 g in 10 TOPICAL CLOTH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 175 g of CHO (HIGH)
Trial: 12905095
Drug: 50 g
RxNorm normalized name: glucose 50 g/296 mL oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 g of CHO (LOW)
Trial: 10711610
Drug: Systemic ofloxacin
RxNorm normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Systemic ofloxacin therapy (2x200 mg/d for 5 days) as adjunct to flap surgery
Trial: 1294304
Drug: Oral sugar
RxNorm normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral sugar clearance
Trial: 1294304
Drug: Long oral
RxNorm normalized name: long pepper extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long oral clearance time
Trial: 7040955
Drug: Sodium nitroprusside
RxNorm normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sodium nitroprusside intravenous infusion